Company intelligence / Profile preview

Latecba

Ownership: Private
Development stage: Commercial

Overview

The Latecba modular stent-graft demonstrated both experimental and clinical efficacy for deployment in patients with short aortic necks (<15 mm), indicating its utility in challenging endovascular aneurysm repair cases. The referenced study analyzed explanted devices, suggesting real-world use and post-market evaluation[1].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Seta Latecba Stent Grafts

Commercial

Indications: Abdominal aortic aneurysm

Beyond the preview

Go deeper on Latecba.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latecba.

Explore the full profile